Leiden,The Netherlands,Jan. 16, 2014(GLOBE NEWSWIRE) –Prosensa Holding N.V.(NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet medical need, today announced initial findings from […]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 15, 2014– Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced data through Week 120 from Study 202, a Phase IIb open-label extension study of […]
Dear Patient Group Representative, We are writing as we would like to share with you that as of January 12, 2014, Prosensa has regained the rights to drisapersen from GSK […]
LEIDEN, Netherlands and LONDON, Jan. 13, 2014 (GLOBE NEWSWIRE) — Prosensa Holding N.V. (Nasdaq:RNA) and GlaxoSmithKline (GSK) today announced that Prosensa has regained all rights from GSK to […]
Help CureDuchenne Now! With only 5 days left in the year, CureDuchenne is doing all it can to raise the dollars needed to fund promising and innovative research to find […]
My son, Justin Paul Monastesse, was a gift and he lived with Duchenne for more than 25 years. Justin always had a great time even though it took 2 1/2 […]
Dear Patient Group Representative, On the 20th of September this year, we shared the results about our Phase III study (DMD114044) of drisapersen in boys with Duchenne Muscular Dystrophy […]
Click here for the recorded webinar: https://cc.readytalk.com/cc/playback/Playback.do?id=2lyea5 CureDuchenne has been an early and important funder of exon skipping research for Duchenne. As we gain visibility to an actual therapeutic with exon […]
The “U.S. Conference on Rare Diseases & Orphan Products: The New Era in Health Care” hosted by DIA and the National Organization for Rare Disorders (NORD) was held in Bethesda, […]
